AbbVie stock advances on a strong 2025 base

AbbVie Inc. (US00287Y1091) leans on a 2025 operating base of USD 56.33 billion in revenue and USD 4.85 in adjusted diluted EPS, with the latest quarterly dividend set at USD 1.64 per share. The company also reported USD 57.0 billion in full-year net revenue for 2024, up 3.7% from 2023, giving AbbVie stock a measurable comparison point even without a fresh event in hand.

Revenue and earnings base

AbbVie said 2025 revenue reached USD 56.33 billion, while adjusted diluted EPS came in at USD 4.85 for the year. That compares with 2024 net revenue of USD 57.0 billion, which AbbVie said was 3.7% higher than 2023, showing how much the company still depends on scale and portfolio mix.

For investors, the most useful number is the earnings base rather than a slogan. AbbVie also reported that adjusted net revenue for 2024 was supported by Humira, Skyrizi, and Rinvoq, three products that remain central to the companys cash generation.

Dividend and balance sheet

AbbVie declared a quarterly dividend of USD 1.64 per share for the latest payment cycle, extending its long record of returning cash to shareholders. The company said 2025 adjusted diluted EPS of USD 4.85 remained the key lens for coverage, because recurring cash flow matters more than any single trading session.

The comparison also matters because the 2024 revenue base of USD 57.0 billion already sat above the prior year by 3.7%. That gives AbbVie stock a concrete reference point for growth expectations, even before the next report or guidance update.

Humira still matters

Humira remains the clearest product reference point in AbbVie’s recent history, even as newer immunology brands have taken a larger role. AbbVie has repeatedly framed Skyrizi and Rinvoq as the follow-on growth engines after the U.S. erosion of Humira, which keeps portfolio transition at the center of the stock story.

The product mix matters because the 2024 revenue figure of USD 57.0 billion was not driven by one line alone. Instead, AbbVie’s transition toward newer immunology assets shapes how the market reads the 2025 earnings base of USD 4.85 per share.

Price context

AbbVie stock trades on the New York Stock Exchange under the ticker NYSE: ABBV. The companys 2025 revenue of USD 56.33 billion and adjusted diluted EPS of USD 4.85 provide the current fundamental anchor, while the latest quarterly dividend of USD 1.64 per share gives the share a second, income-focused support point.

In market terms, those numbers matter more than any short-term noise. AbbVie stock remains a large-cap health care name built around cash flow, dividends, and the continued performance of Skyrizi, Rinvoq, and the post-Humira portfolio.

Read deeper on AbbVie

AbbVie stock is best understood through its 2025 earnings base, its 2024 revenue comparison, and the latest dividend step-up. Those three figures tell the core story of scale, transition, and shareholder return.